Pharmaust enters exciting phase 2 trial of Cancer drug
Leading ASX listed Cancer drug specialist Pharmaust, are in discussions with a UK-based clinical oncologist to evaluate their anti-cancer drug known as Monepantel in patients with oesophageal cancer.
The evaluation of the company’s Monepantel drug will constitute a phase 2 trial following on from the successful phase 1 trials undertaken last year.
Similar studies of two other cancers will also be undertaken in Australia and the USA in order identify which leading cancers PharmAust should pursue for development and product registration purposes.
The trials, which will analyse the effect of Monepantel on patient’s tumours are designed to provide short term feedback on the efficacy of the drug.
After obtaining feedback from its phase 1 trials Pharmaust elected to change the way Monepantel was taken by producing capsules of the product. In response to specific feedback from patients, Pharmaust have now made the capsule tasteless which the company expects will assist in its administration to patients.
The latest trial which will be conducted on patients who have not responded to standard anti-cancer treatment is expected to commence within the next 8-10 weeks when the new tasteless capsules become available.